Product Description
a Toll like receptor-2 agonist targeting desmocollin-3 as a first-line therapy in advanced non-small-cell lung cancer (NSCLC). (Sourced from: https://pubmed.ncbi.nlm.nih.gov/27831503/)
Mechanisms of Action: CD44 Blocker
Novel Mechanism: Yes
Modality: Large Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Cadila Pharmaceuticals
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Melanoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CR-60/4051 | P2 |
Terminated |
Melanoma |
2010-12-01 |